Fda Rejects Mdma As A Psychedelic Treatment For Ptsd

FDA Declines to Approve Psychedelic Drug MDMA for PTSD Treatment

Panel Cites Safety Concerns

Patients and Advocates Disappointed

WASHINGTON, March 10, 2023 - Federal health regulators on Friday declined to approve the psychedelic drug MDMA-assisted therapy, commonly known as ecstasy, as a treatment for post-traumatic stress disorder (PTSD). The U.S. Food and Drug Administration (FDA) made the decision after reviewing data from clinical trials conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit organization that has been studying the potential therapeutic uses of MDMA for over 25 years.

In a statement, the FDA said that it had concerns about the safety of MDMA-assisted therapy, particularly its potential for abuse and misuse. The agency also said that the data from the clinical trials was not sufficient to demonstrate the effectiveness of the therapy for treating PTSD.

The decision is a setback for MAPS and other advocates for the use of psychedelics in psychotherapy. They argue that MDMA-assisted therapy is a safe and effective treatment for PTSD, and that it has the potential to help millions of people who suffer from this debilitating condition.

In a statement, MAPS said that it was "disappointed" by the FDA's decision, but that it would continue to work to make MDMA-assisted therapy available to patients.